It’s startling to learn that over 30% of the U.S. population has some degree of non-alcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver and the most common type of liver disease in the Western world
Stephen Harrison, MD, from Pinnacle Clinical Research, discusses how specialists can help educate primary care physicians (PCPs) more on non-alcoholic fatty liver disease (NAFLD), the importance of PCPs recognizing which individuals with NAFLD can progress to more sever liver disease, and more.
A growing number of healthcare providers are adopting FibroScan, a non-invasive technology to examine patient’s liver at the point of care.
Stephen Harrison, MD, from Pinnacle Clinical Research, discusses the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in the United States, the correlation between NAFLD and obesity, and more.
This white paper examines the impact of NAFLD and NASH as both a medical and economic crisis among military and civilian populations, and highlights the VA’s strategy to eradicate liver disease, including its broadened contract with Echosens to include the FibroScan mini+ portable technology